aclidinium vs cromolyn
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of aclidinium and cromolyn. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Tudorza Pressair
Intal
No summary available.
Cromolyn (Intal) is a medicine that helps manage mastocytosis, a condition where you have too many mast cells. It can help improve symptoms like diarrhea and flushing.
Information not available.
Cromolyn is used to manage mastocytosis. Mastocytosis is a condition where you have too many mast cells in your body. This medicine can help improve symptoms like diarrhea, flushing, headaches, vomiting, hives, abdominal pain, nausea, and itching.
Information not available.
Cromolyn works by preventing mast cells from releasing substances that cause symptoms. It stabilizes these cells. This helps to reduce the symptoms of mastocytosis.
- • Upper respiratory infection
- • Headache
- • Back pain
- • Headache
- • Diarrhea
- Difficulty breathing 1,869
- Inhaler not working correctly 1,281
- Skipped a dose of medicine 1,017
- Asthma 814
- Chronic obstructive pulmonary disease (COPD) 764
- Treatment Failure 1,004
- Fatigue 207
- Nausea 183
- Headache 178
- Diarrhoea 153
No specific warnings noted.
You should not take this medicine if you are allergic to cromolyn sodium.
No pregnancy information available.
In animal studies, cromolyn sodium alone did not cause harm during pregnancy. Talk to your doctor if you are pregnant or breastfeeding before taking this medicine.
Also Compare, Nearby Drugs
Compare aclidinium with
How to Read This aclidinium vs cromolyn Comparison
aclidinium is classified in the Long-Acting Muscarinic Antagonist (LAMA) drug class, while cromolyn sits within the Mast Cell Stabilizer class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, aclidinium has 5,745 submissions while cromolyn has 1,725. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for aclidinium or cromolyn.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.